Saturday 17 October 2026
Export ZURA’s income statement to Excel — free account
Zura Bio Limited
ZURA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.5% and free cash flow fell 30.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.88
0.40
−9.35%
Follow ZURA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(47.30%) | (79.52%) | (59.52%) | (71.76%) | |
| (37.55%) | (67.71%) | (52.92%) | (62.74%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(53.47%) | (99.33%) | (49.28%) | (59.92%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.57) | (0.69) | (0.65) | (0.61) | |
Free Cash Flow |
(53.50) | (64.93) | (72.75) | (77.63) | |
Capital Expenditures |
(0.14) | (0.11) | (0.08) | (0.09) | |
| Other line items | |||||
Cash ROIC |
(21.50%) | (30.78%) | (16.44%) | (19.30%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.85 | 0.65 | 0.68 | 0.67 | |
Depreciation/Fixed assets |
0.30 | 0.39 | 0.45 | 0.41 | |
Capex/Depreciation |
(3.62) | (2.31) | (1.37) | (1.41) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.56) | (0.69) | (0.65) | (0.61) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates